promo_leaderboard Ad
‹ All stocks
ARQT

Arcutis Biotherapeutics

ARQT · NASDAQ · Healthcare
$27.06
▼ $0.09 (-0.33%)
$23.67 $26.72 $29.77 $32.82 $27.06 Sep 2026 Oct 2026 Nov 2026
Day range
$26.90 – $27.31
Year range
$19.30 – $34.80
Open
$27.13
Previous close
$27.15
Market cap
$3.42B
Volume (24h)
$66.6K
Volume (52w)
$1.80M
Performance
7D
▼ -1.20%
1M
▼ -15.15%
3M
▲ 2.27%
6M
▲ 28.80%
1Y
▲ 3.40%
YTD
▼ -6.69%
3Y
▲ 1207.25%
5Y
▲ 43.63%
All-time
▲ 24.13%
Key statistics
P/E ratio
128.86
EPS (TTM)
$0.21
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
126.5M
About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.

Visit website
Country: United States of America
More in Healthcare